Rothschild & Co Redburn has revised its price target for Zimmer Biomet Holdings, Inc. (ZBH) from $125 to $115, while reaffirming a “Buy” rating on the stock. This adjustment comes amidst a flurry of analyst activity, with several other firms also updating their price targets for Zimmer Biomet. The company recently reported its Q4 2025 earnings, beating estimates on strong implant demand and announcing a $1.5 billion equity buyback plan.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Rothschild & Co Redburn Adjusts Zimmer Biomet PT to $115 From $125, Maintains Buy Rating
Rothschild & Co Redburn has revised its price target for Zimmer Biomet Holdings, Inc. (ZBH) from $125 to $115, while reaffirming a “Buy” rating on the stock. This adjustment comes amidst a flurry of analyst activity, with several other firms also updating their price targets for Zimmer Biomet. The company recently reported its Q4 2025 earnings, beating estimates on strong implant demand and announcing a $1.5 billion equity buyback plan.